ImmunityBio Hit with Class Action Over Anktiva Claims—Key Facts and Investor Implications

Lawsuit Centers on Alleged Overstatements of Anktiva’s Potential

A class action lawsuit has been filed against ImmunityBio (NASDAQ: IBRX) in the United States District Court for the Central District of California, focusing on alleged false and misleading statements related to the company’s cancer therapy, Anktiva. According to the suit, ImmunityBio—led by founder Patrick Soon-Shiong—materially overstated Anktiva's capabilities, leading investors to potentially misjudge the company’s business outlook and prospects.

Filing Period and Key Allegations Detailed in the Complaint

The lawsuit is open to anyone who acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The core allegations are twofold: (1) ImmunityBio’s leadership overstated the effectiveness of Anktiva, and (2) as a result, public statements regarding the company’s business and operational status may have significantly misled investors. When the true nature of Anktiva and related business prospects came to light, the lawsuit claims shareholders suffered notable financial losses.

What This Means for Shareholders: Legal Rights and Next Steps

Investors who purchased ImmunityBio stock during the Class Period and experienced losses are being urged by Bragar Eagel & Squire, P.C.—a law firm specializing in stockholder rights—to inquire about joining the suit as a lead plaintiff before the May 26, 2026 deadline. There is no associated cost or obligation for contacting the firm, and further details are available via phone, email, or an online contact form.

Underlying Questions for ImmunityBio’s Future

The case raises pressing questions about the accuracy of recent corporate communications—particularly those related to ImmunityBio’s pipeline and the potential market impact of Anktiva. If the allegations stand up in court, the fallout could extend beyond direct investors; market confidence in ImmunityBio management may also be challenged during this sensitive period.

Takeaway: Upcoming Deadline and Investor Considerations

As the May 26th deadline to seek lead plaintiff status approaches, ImmunityBio stockholders should carefully consider both the claims being brought forward and potential developments in the company’s regulatory or clinical trajectory. For investors, understanding whether this lawsuit signals broader risks—or is a temporary storm likely to pass—could shape how they approach the stock heading into the summer.

For further information or to participate in the action, contact Bragar Eagel & Squire, P.C. at (212) 355-4648 or visit www.bespc.com.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI